1. Home
  2. EXEL

EXEL

Exelixis Inc.

Logo Exelixis Inc.

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

as 04-19-2024 4:00pm EST

$
-
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

Founded: 1994 Country:
United States
United States
Employees: N/A City: ALAMEDA
Market Cap: 6.6B IPO Year: 2000
Target Price: $26.79 AVG Volume (30 days): 2.3M
Analyst Decision: Buy Number of Analysts: 14
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: 0.65 EPS Growth: 16.07
52 Week Low/High: $18.08 - $24.34 Next Earning Date: 04-30-2024
Revenue: $1,830,208,000 Revenue Growth: 13.60%
Revenue Growth (this year): 6.11% Revenue Growth (next year): 8.39%

Share on Social Networks:

Stock Insider Trading Activity of Exelixis Inc. (EXEL)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Garber Alan M EXEL Director Mar 21 '24 Sell $24.01 19,205 $461,112.05 35,703 SEC Form 4